Form 8-K - Current report:
SEC Accession No. 0000950170-25-088169
Filing Date
2025-06-20
Accepted
2025-06-20 07:05:27
Documents
11
Period of Report
2025-06-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-20250618.htm   iXBRL 8-K 159156
2 EX-10.1 eypt-ex10_1.htm EX-10.1 16410
  Complete submission text file 0000950170-25-088169.txt   286589

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eypt-20250618.xsd EX-101.SCH 23898
13 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20250618_htm.xml XML 4523
Mailing Address 480 PLEASANT STREET SUITE C400 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE C400 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 251059061
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)